Drugs / magnesium hydroxide
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | PEPCID COMPLETE | — | 2000-10-16 | fda.gov ↗ |
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04368585 | Jul → Aug 2020 | — | Spero Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04324905 | Apr → Oct 2020 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT05109390 | Jul → Oct 2018 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02382640 | Mar → May 2015 | — | Takeda | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04382157 | Feb 2020 → Aug 2022 | magnesium deficiency | Oslo University Hospital | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01037452 | Dec 2009 → Jan 2010 | dyspepsia | Novartis | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04802785 | Jun → Jul 2021 | — | Dinara Zhumanbayeva | Unknown | No outcome recorded |
| Comparator or background therapy7 trials | ||||||
| Phase 1 | NCT05028673 Background | Aug → Dec 2021 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 2 | NCT06503978 Background | Aug 2024 → Jul 2025 overdue | autism spectrum disorder, constipation disorder, diarrheal disease | Gut-Brain-Axis Therapeutics Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06321796 Background | Feb 2024 → Feb 2025 | Pitt-Hopkins syndrome | Gut-Brain-Axis Therapeutics Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT01336530 Comparator | Apr 2011 → Jan 2017 | radiation-induced disorder | MEDA Pharma GmbH & Co. KG | Terminated | No outcome recorded |
| Phase 4 | NCT05216328 Comparator | Dec 2022 → Jan 2027 expected | opioid-induced constipation | Amsterdam UMC, location VUmc | Recruiting | No outcome recorded |
| Phase 4 | NCT01773096 Background | May 2013 → May 2015 | constipation disorder | Shriners Hospitals for Children | Completed | No outcome recorded |
| Phase 4 | NCT01281501 Background | Jan → Oct 2011 | dyspepsia | Chulalongkorn University | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | magnesium hydroxide | “The fixed-dose combination of esomeprazole and magnesium hydroxide showed rapid absorption and quicker gastric acid suppression than enteric-coated esomeprazole with comparable...” PMID 39289057 ↗ Sep 202413“Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL or equivalent” NCT02382640 ↗ “Each 5 ml consists of Aluminum Hydroxide - 200 mg, Magnesium Hydroxide - 200 mg, and Simethicone - 20 mg.” NCT06321796 ↗ “Each 5 ml consists of Aluminum Hydroxide - 200 mg, Magnesium Hydroxide - 200 mg, and Simethicone - 20 mg.” NCT06503978 ↗ “30 ml of oral antacid (1.32 grams of aluminum hydroxide, 0.72 grams of magnesium hydroxide)” NCT01281501 ↗ “Aluminum hydroxide and magnesium hydroxide” NCT05028673 ↗ “Slow-released magnesium hydroxide” NCT04382157 ↗ |
| Route | Oral | “30 ml of oral antacid (1.32 grams of aluminum hydroxide, 0.72 grams of magnesium hydroxide)” NCT01281501 ↗ |